Plasma TFPI activity after intravenous injection of pentasaccharide (PS) and unfractionated heparin in rabbits

Zitoun, D.; Bara, L.; Bloch, Marie-Françoise; Samama, M

doi:10.1016/0049-3848(94)90232-1

Cited by 14 publications

(5 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…administration of up to 200 p,g/kg of SR 90107NOrg 31540 to rabbits (45), or S.C. injection of 18 mg of SR 90107NOrg 3 1540 to human healthy volunteers (20). In contrast, injection of comparable dosages of heparin or low molecular weight heparin induced a sizeable increase in TFPI concentration in plasma (20,45).…”

Section: Release Of Tissue Factor Pathway Inhibitor (Tfpi)mentioning

confidence: 99%

SR 90107A/Org 31540, a Novel Anti‐Factor Xa Antithrombotic Agent

Petitou

Lormeau

et al. 1997

Cardiovascular Drug Reviews

View full text Add to dashboard Cite

Section: Release Of Tissue Factor Pathway Inhibitor (Tfpi)mentioning

confidence: 99%

SR 90107A/Org 31540, a Novel Anti‐Factor Xa Antithrombotic Agent

Petitou

Lormeau

et al. 1997

Cardiovascular Drug Reviews

View full text Add to dashboard Cite

“…It is also released by ultra low molecular weight heparins [36], but it is probably not released significantly by the pentasaccharide [36,37]. Other glycosaminoglycans, e.g., pentosan polyphosphate [38] may also release TFPI, whereas dermatan sulfate probably does not release significant amounts of TFPI [38].…”

Section: Degradation Of Tfpimentioning

confidence: 99%

Tissue Factor Pathway Inhibitor (Tfpi) – An Update

Sandset

1996

Pathophysiol Haemos Thromb

View full text Add to dashboard Cite

There is compelling experimental evidence that tissue factor pathway inhibitor (TFPI) exerts important role(s) as a natural anticoagulant. Iinmunodepletion of TFPI lowers the treshold by which tissue factor (TF) can induce disseminated intravascular coagulation. Conversely, infusion of recombinant TFPI protects against thrombosis and disseminated intravascular coagulation in numerous experimental models. Since TFPI mutants associated with thrombosis have not yet been identified, a definite role of TFPI in coagulation is yet to be assigned. Current research on TFPI is mainly focused on the cell biology of TFPI, on the contribution of TFPI to the anticoagulant action of heparins, and on the role of lipoprotein-associated TFPI. TFPI is produced constitutively in endothelial cells, and is to a great extent bound to its surface. The binding molecule(s) have not yet been characterized, but TFPI is rapidly released by heparin and other negatively charged ions. In other cell lines degradation of TFPI is mediated by the low density lipoprotein receptor-related protein, which may be important for its clearance. In plasma, TFPI contributes strongly to the postheparin anticoagulant effect seen in dilute prothrombin time assays. The effect is probably mediated by redistribution of TFPI. Moreover, in the presence of heparin, antithrombin and TFPI cooperate to inhibit activation of coagulation. Antithrombin abrogates activation of factor VII bound to TF, whereas TFPI inhibits factor VIIa/TF complexes formed. The role of lipoprotein associated TFPI is still essentially unknown, but may play an important role in atherosclerosis.

show abstract

“…[39], fucoidan [40] and depolymerized holothurian GAG [41]. TFPI is not released by the specific pentasaccharide sequence of heparins with high affinity for antithrombin [42] and it is not released by dermatan sulphate [39]. Protamine sulphate abrogates the release of TFPI by heparins [35,43], which may be an effect of displacement from heparin.…”

Section: Introductionmentioning

confidence: 99%

Physiological Function of Tissue Factor Pathway Inhibitor and Interaction with Heparins

Sandset

Bendz²,

Hansen³

2000

Pathophysiol Haemos Thromb

View full text Add to dashboard Cite

Tissue factor pathway inhibitor (TFPI) is now recognized as a major physiological anticoagulant. Its main role is to modulate factor VIIa/tissue factor catalytic activity. Another important role is to potentiate the effect of heparins. TFPI is released from the vascular endothelium after injection of either unfractionated heparin (UFH) or low-molecular-weight heparins (LMWHs), which may then provide high concentrations of TFPI at sites of tissue damage and ongoing thrombosis. In dilute prothrombin-time-based assays, released TFPI contributes approximately one-third to the anticoagulant effect of heparin, the remaining being accounted for by antithrombin. Released TFPI, but not plasma TFPI, contains the basic carboxy-terminal tail which is important for the anticoagulant effect. UFH and LMWH exert differential effects on intravascular TFPI. UFH, but not LMWH, given in therapeutic doses, is associated with a progressive depletion of TFPI, which is associated with a strong rebound activation of coagulation after cessation of treatment. Such depletion may explain the apparent superior efficacy of LMWH observed in clinical trials.

show abstract

Plasma TFPI activity after intravenous injection of pentasaccharide (PS) and unfractionated heparin in rabbits

Cited by 14 publications

References 7 publications

SR 90107A/Org 31540, a Novel Anti‐Factor Xa Antithrombotic Agent

SR 90107A/Org 31540, a Novel Anti‐Factor Xa Antithrombotic Agent

Tissue Factor Pathway Inhibitor (Tfpi) – An Update

Physiological Function of Tissue Factor Pathway Inhibitor and Interaction with Heparins

Contact Info

Product

Resources

About